<DOC>
	<DOCNO>NCT00548587</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled study determine safety tolerability E5555 subject Acute coronary syndrome ( ACS ) .</brief_summary>
	<brief_title>Safety Tolerability E5555 Its Effects Markers Intravascular Inflammation Subjects With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Males Females , 45 80 year age 2 . Presenting feature nonST segment elevation ACS ( unstable angina Myocardial infarction without persistent ST elevation ) . least one follow two criterion admission : Cardiac enzymesâ‰¥ ULN local institution OR ECG change compatible ischemia 3 . Randomisation possible within 24 hour onset recent symptomatic episode . EXCLUSION CRITERIA : 1 . History acquire congenital bleeding disorder , coagulopathy platelet disorder , history pathological bleeding within last 6 month 2 . History intracranial bleeding , history hemorrhagic retinopathy , history recent ischemic stroke transient ischemic attack , know structural cerebral vascular lesion 3 . Recent trauma , major surgery , Percutaneous coronary intervention coronary artery surgery 4 . Clinically significant haematological , hepatic renal abnormality 5 . Patients specific STsegment change , severe congestive heart failure uncontrolled cardiac arrhythmia baseline 6 . Recent significant ( determined investigator ) cardiovascular event</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
</DOC>